Conditions: Cancer Carcinoma Head and Neck Cancer Metastases Metastatic Cancer Metastatic or Recurrent Squamous Cell Carcinoma of Head and Neck Oncology Squamous Cell Carcinoma Tumors
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 52
Healthy volunteers: no

Brief summary:
To estimate the effect of second-line panitumumab monotherapy on objective response in patients with metastatic or recurrent squamous cell carcinoma of head and neck (SCCHN).

Detailed description:

Arms:
arm 1: articipants received panitumumab as an intravenous infusion at a dose of 9 mg/kg every 21 days until disease progression, unacceptable toxicity, withdrawal of consent, death, or end of study.

Interventions: intervention 1: Panitumumab
Intervention descriptions: intervention 1: Panitumumab was administered over a 1 hour intraveneous (IV) infusion at a dose of 9 mg/kg every 21 days.

Protocol document: